Status:
ENROLLING_BY_INVITATION
SGLT2 Inhibitors in Treating Patients With PCOS
Lead Sponsor:
Shanghai 10th People's Hospital
Conditions:
Polycystic Ovary Syndrome
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
Chronic inflammation is the core of Polycystic ovary syndrome (PCOS), and obesity and overweight further exacerbate the level of inflammation in the peripheral circulation and ovarian tissue in PCOS p...
Detailed Description
This clinical study is a prospective, single-center, randomized (1:1) controlled clinical study. The enrollment population is overweight or obese PCOS patients. After signing the informed consent form...
Eligibility Criteria
Inclusion
- Female aged 18-45
- Meet Rotterdam criteria
- BMI≥20kg/m2
Exclusion
- Treatment with any additional medications that might impede the trial, including GLP-1 RAs, metformin, pioglitazone, contraceptives, or traditional Chinese medicine within the past 3 months
- Pregnancy or lactation
- Mental illness
- Malignant tumors
- Chronic kidney disease or severe liver dysfunction
- Inflammatory bowel disease
- Involvement in other research programs within the past 3 months
Key Trial Info
Start Date :
November 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05966792
Start Date
November 10 2023
End Date
June 30 2025
Last Update
June 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Tenth People'S Hospital
Shanghai, Shanghai Municipality, China, 200072